Bispecific killer cell engager with high affinity and specificity toward cd16a on nk cells for cancer immunotherapy

HIGHLIGHTS

• who: Shahryar Khoshtinat Nikkhoi and colleagues from the United Kingdom Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United States, Department of have published the research: Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy, in the Journal: (JOURNAL)
• what: The aim of this study was to develop a bispecific killer cell engager (BiKE) with high affinity and specificity/selectivity toward CD16a receptor for NK cellbased cancer immunotherapy. The results of this experiment showed that C1 VHH effectively bound to CD16a receptor on NK92 cells without cross-reactivity . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.